Clinical characteristics of the MMUD and MUD cohorts
| . | MUD, n (%) . | Disease status (S/R) . | MMUD, n (%) . | Disease status (S/R) . |
|---|---|---|---|---|
| Diagnosis | ||||
| LG-NHL | 23 (21) | 23/0 | 8 (16) | 6/2 |
| Transformed LG-NHL | 2 (2) | 2/0 | 2 (4) | 2/0 |
| INT/HG-NHL | 13 (12) | 12/1 | 11 (22) | 11/0 |
| Chronic lymphocytic leukemia | 5 (5) | 5/0 | 2 (4) | 2/0 |
| Hodgkin lymphoma | 21 (20) | 16/5 | 5 (10) | 3/2 |
| Plasma cell disorders | 10 (9) | 9/1 | 6 (12) | 5/1 |
| Acute myeloid leukemia | 17 (16) | 16/1 | 6 (12) | 6/0 |
| Acute lymphoblastic leukemia | 1 (1) | 1/0 | 1 (2) | 1/0 |
| Chronic phase CML | 3 (3) | 3/0 | 1 (2) | 1/0 |
| Idiopathic myelofibrosis | 5 (5) | N/A | 5 (10) | N/A |
| Myelodysplasia | 3 (3) | N/A | 3 (6) | N/A |
| Other | 4 (4) | N/A | 0 (0) | N/A |
| Seattle risk group19 | ||||
| Low | 41 (38) | 20 (40) | ||
| Standard | 23 (21) | 10 (20) | ||
| High | 39 (36) | 20 (40) | ||
| Not applicable | 4 (4) | 0 (0) | ||
| Median age, y (range) | 48 (13-65) | 48 (18-67) | ||
| Sex | ||||
| Female | 41 (38) | 22 (44) | ||
| Male | 66 (62) | 28 (56) | ||
| Lines of treatment | ||||
| Median (range) | 4 (0-9) | 3 (1-8) | ||
| Prior autograft | 46 (43) | 19 (38) | ||
| Chemosensitive disease* | 87 (92) | 37 (88) |
| . | MUD, n (%) . | Disease status (S/R) . | MMUD, n (%) . | Disease status (S/R) . |
|---|---|---|---|---|
| Diagnosis | ||||
| LG-NHL | 23 (21) | 23/0 | 8 (16) | 6/2 |
| Transformed LG-NHL | 2 (2) | 2/0 | 2 (4) | 2/0 |
| INT/HG-NHL | 13 (12) | 12/1 | 11 (22) | 11/0 |
| Chronic lymphocytic leukemia | 5 (5) | 5/0 | 2 (4) | 2/0 |
| Hodgkin lymphoma | 21 (20) | 16/5 | 5 (10) | 3/2 |
| Plasma cell disorders | 10 (9) | 9/1 | 6 (12) | 5/1 |
| Acute myeloid leukemia | 17 (16) | 16/1 | 6 (12) | 6/0 |
| Acute lymphoblastic leukemia | 1 (1) | 1/0 | 1 (2) | 1/0 |
| Chronic phase CML | 3 (3) | 3/0 | 1 (2) | 1/0 |
| Idiopathic myelofibrosis | 5 (5) | N/A | 5 (10) | N/A |
| Myelodysplasia | 3 (3) | N/A | 3 (6) | N/A |
| Other | 4 (4) | N/A | 0 (0) | N/A |
| Seattle risk group19 | ||||
| Low | 41 (38) | 20 (40) | ||
| Standard | 23 (21) | 10 (20) | ||
| High | 39 (36) | 20 (40) | ||
| Not applicable | 4 (4) | 0 (0) | ||
| Median age, y (range) | 48 (13-65) | 48 (18-67) | ||
| Sex | ||||
| Female | 41 (38) | 22 (44) | ||
| Male | 66 (62) | 28 (56) | ||
| Lines of treatment | ||||
| Median (range) | 4 (0-9) | 3 (1-8) | ||
| Prior autograft | 46 (43) | 19 (38) | ||
| Chemosensitive disease* | 87 (92) | 37 (88) |
UD cohorts stratified according to 10/10 HLA match (MUD) or 6 to 9/10 HLA match (MMUD). All P values for heterogeneity (χ2 test) were not significant between MUD and MMUD groups.
NHL indicates non-Hodgkin lymphoma; CML, chronic phase leukemia; N/A, not applicable; LG, low grade; INT/HG, intermediate/high grade; S, chemosensitive disease; and R, chemoresistant disease.
Excluding “not applicable” cases.